Camrelizumab, Tislelizumab and Sintilimab are all PD-1 inhibitors, of which Sindilizumab is the first PD-1 monoclonal antibody to enter China’s medical insurance catalog and also has the most first-line indications, including NSCLC. This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.